The economics of improving medication adherence in osteoporosis: Validation and application of a simulation model

Journal of Clinical Endocrinology and Metabolism

Volumn 96, Issue 9, 2011, Pages 2762-2770

  Patrick, Amanda R ^a   Schousboe, John T ^b   Losina, Elena ^a   Solomon, Daniel H ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID;

ADULT; AGED; ARTICLE; CLINICAL EFFECTIVENESS; COMPUTER SIMULATION; CONTROLLED STUDY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; COST MINIMIZATION ANALYSIS; DRUG EFFICACY; DRUG WITHDRAWAL; EVALUATION RESEARCH; FEMALE; FOREARM FRACTURE; FRAGILITY FRACTURE; HEALTH CARE UTILIZATION; HIP FRACTURE; HUMAN; MALE; OSTEOPOROSIS; PATIENT ATTITUDE; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROCESS DEVELOPMENT; QUALITY ADJUSTED LIFE YEAR; VERTEBRA FRACTURE;

AGED; BONE DENSITY CONSERVATION AGENTS; COST-BENEFIT ANALYSIS; DIPHOSPHONATES; FEMALE; FRACTURES, BONE; HUMANS; MEDICATION ADHERENCE; MIDDLE AGED; MODELS, ECONOMIC; OSTEOPOROSIS; QUALITY-ADJUSTED LIFE YEARS; TREATMENT OUTCOME;

EID: 80052522271     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2011-0575     Document Type: Article

References (40)

1. Burge R., Dawson-Hughes B., Solomon D.H., Wong J.B., King A., Tosteson A. 2007 Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025. J Bone Miner Res 22:465-475 (Pubitemid 46797130)
2. Cranney A., Guyatt G., Griffith L., Wells G., Tugwell P., Rosen C. 2002 Meta-analyses of therapies for postmenopausal osteoporosis. IX: Summary of meta-analyses of therapies for postmenopausal osteoporosis. Endocr Rev 23:570-578 (Pubitemid 34925651)
3. Kothawala P., Badamgarav E., Ryu S., Miller R.M., Halbert R.J. 2007 Systematic review and meta-analysis of real-world adherence to drug therapy for osteoporosis. Mayo Clin Proc 82:1493-1501 (Pubitemid 350211697)
4. Blouin J., Dragomir A., Moride Y., Ste-Marie L.G., Fernandes J.C., Perreault S. 2008 Impact of noncompliance with alendronate and risedronate on the incidence of nonvertebral osteoporotic fractures in elderly women. Br J Clin Pharmacol 66:117-127 (Pubitemid 351822168)
5. Curtis J.R., Westfall A.O., Cheng H., Lyles K., Saag K.G., Delzell E. 2008 Benefit of adherence with bisphosphonates depends on age and fracture type: Results from an analysis of 101,038 new bisphosphonate users. J Bone Miner Res 23:1435-1441
6. Briesacher B.A., Andrade S.E., Harrold L.R., Fouayzi H., Yood R.A. 2010 Adoption of once-monthly oral bisphosphonates and the impact on adherence. Am J Med 123:275-280
7. Cotté F.E., Fardellone P., Mercier F., Gaudin A.F., Roux C. 2010 Adherence to monthly and weekly oral bisphosphonates inwomenwith osteoporosis. Osteoporos Int 21:145-155
8. Gold D.T., Trinh H., Safi W. 2009 Weekly versus monthly drug regimens: 1-year compliance and persistence with bisphosphonate therapy. Curr Med Res Opin 25:1831-1839
9. Gleeson T., Iversen M.D., Avorn J., Brookhart A.M., Katz J.N., Losina E., May F., Patrick A.R., Shrank W.H., Solomon D.H. 2009 Interventions to improve adherence and persistence with osteoporosis medications: A systematic literature review. Osteoporos Int 20:2127-2134
10. Solomon D.H., Gleeson T., Iversen M., Avorn J., Brookhart M.A., Lii J., Losina E., May F., Patrick A., Shrank W.H., Katz J.N. 2010 A blinded randomized controlled trial of motivational interviewing to improve adherence with osteoporosis medications: Design of the OPTIMA trial. Osteoporos Int 21:137-144
11. TostesonA.N.,Jönsson B., Grima D.T., O'Brien B.J., Black D.M., Adachi J.D. 2001 Challenges for model-based economic evaluations of postmenopausal osteoporosis interventions. Osteoporos Int 12:849-857 (Pubitemid 33086272)
12. Schousboe J.T. 2007 Cost-effectiveness modeling research of pharmacologic therapy to prevent osteoporosis-related fractures. Curr Rheumatol Rep 9:50-56 (Pubitemid 46806308)
13. Ström O., Borgström F., Kanis J.A., Jönsson B. 2009 Incorporating adherence into health economic modelling of osteoporosis. Osteoporos Int 20:23-34
14. Hiligsmann M., Gathon H.J., Bruyère O., Ethgen O., Rabenda V., Reginster J.Y. 2010 Cost-effectiveness of osteoporosis screening followed by treatment: The impact of medication Adherence. Value Health 13:394-401
15. Cotté F.E., Fautrel B., De Pouvourville G. 2009 A Markov model simulation of the impact of treatment persistence in postmenopausal osteoporosis. Med Decis Making 29:125-139
16. Weinstein M.C., Siegel J.E., Gold M.R., Kamlet M.S., Russell L.B. 1996 Recommendations of the Panel on Cost-effectiveness in Health and Medicine. JAMA 276:1253-1258 (Pubitemid 26337709)
17. Melton 3rd L.J., Crowson C.S., O'Fallon W.M. 1999 Fracture incidence in Olmsted County, Minnesota: Comparison of urban with rural rates and changes in urban rates over time. Osteoporos Int 9:29-37 (Pubitemid 29086162)
18. Schousboe J.T., Taylor B.C., Fink H.A., Kane R.L., Cummings S.R., Orwoll E.S., Melton 3rd L.J., Bauer D.C., Ensrud K.E. 2007 Cost-effectiveness of bone densitometry followed by treatment of osteoporosis in older men. JAMA 298:629-637 (Pubitemid 47236414)
19. Black D.M., Arden N.K., Palermo L., Pearson J., Cummings S.R. 1999 Prevalent vertebral deformities predict hip fractures and new vertebral deformities but not wrist fractures. Study of Osteoporotic Fractures Research Group. J Bone Miner Res 14:821-828 (Pubitemid 29210609)
20. Melton 3rd L.J., Ilstrup D.M., Beckenbaugh R.D., Riggs B.L. 1982 Hip fracture recurrence. A population-based study. Clin Orthop Relat Res 167:131-138 (Pubitemid 12090650)
21. Cuddihy M.T., Gabriel S.E., Crowson C.S., O'Fallon W.M., Melton 3rd L.J. 1999 Forearm fractures as predictors of subsequent osteoporotic fractures. Osteoporos Int 9:469-475 (Pubitemid 29348560)
22. Schousboe J.T., Dowd B.E., Davison M.L., Kane R.L. 2010 Association of medication attitudes with non-persistence and non-compliance with medication to prevent fractures. Osteoporos Int 21:1899-1909
23. Wells G.A., Cranney A., Peterson J.,M.Boucher, Shea B., Robinson V., Coyle D., Tugwell P. 2008 Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev 1:CD001155
24. Sawka A.M., Papaioannou A., Adachi J.D., Gafni A., Hanley D.A., Thabane L. 2005 Does alendronate reduce the risk of fracture in men? A meta-analysis incorporating prior knowledge of anti-fracture efficacy in women. BMC Musculoskelet Disord 6:39
25. Bagger Y.Z., Tankó L.B., Alexandersen P., Ravn P., Christiansen C. 2003 Alendronate has a residual effect on bone mass in postmeno- pausal Danish women up to 7 years after treatment withdrawal. Bone 33:301-307 (Pubitemid 37103246)
26. Weycker D., Macarios D., Edelsberg J., Oster G. 2007 Compliance with osteoporosis drug therapy and risk of fracture. Osteoporos Int 18:271-277 (Pubitemid 46233172)
27. Tosteson A.N., Gottlieb D.J., Radley D.C., Fisher E.S., Melton 3rd L.J. 2007 Excess mortality following hip fracture: The role of underlying health status. Osteoporos Int 18:1463-1472 (Pubitemid 47512685)
28. Von Friesendorff M., Besjakov J., Akesson K. 2008 Long-term survival and fracture risk after hip fracture: A 22-year follow-up in women. J Bone Miner Res 23:1832-1841
29. Kado D.M., Browner W.S., Palermo L., Nevitt M.C., Genant H.K., Cummings S.R. 1999 Vertebral fractures and mortality in older women: A prospective study. Study of Osteoporotic Fractures Research Group. Arch Intern Med 159:1215-1220 (Pubitemid 29269861)
30. Empana J.P., Dargent-Molina P., Bréart G. 2004 Effect of hip fracture on mortality in elderly women: The EPIDOS prospective study. J Am Geriatr Soc 52:685-690 (Pubitemid 38596484)
31. Haentjens P., Magaziner J., Colón-Emeric C.S., Vanderschueren D., Milisen K., Velkeniers B., Boonen S. 2010 Meta-analysis: Excess mortality after hip fracture among older women and men. Ann Intern Med 152:380-390
32. Thomson Healthcare (Firm) 2007 Red book. Montvale, NJ: Thomson
33. Kanis J.A., Johnell O., De Laet C., Jonsson B., Oden A., Ogelsby A.K. 2002 International variations in hip fracture probabilities: Implications for risk assessment. J Bone Miner Res 17:1237-1244 (Pubitemid 34680500)
34. Melton 3rd L.J., Chrischilles E.A., Cooper C., Lane A.W.,Riggs B.L. 1992 Perspective. How many women have osteoporosis? J Bone Miner Res 7:1005-1010
35. Earnshaw S.R., Graham C.N., Ettinger B., Amonkar M.M., Lynch N.O., Middelhoven H. 2007 Cost-effectiveness of bisphosphonate therapies for women with postmenopausal osteoporosis: Implications of improved persistence with less frequently administered oral bisphosphonates. Curr Med Res Opin 23:2517-2529 (Pubitemid 350033454)
36. Thomson Reuters 2010 Red book. Montvale, NJ: Thomson Reuters
37. Oleksik A., Lips P., Dawson A., Minshall M.E., Shen W., Cooper C., Kanis J. 2000 Health-related quality of life in postmenopausal women with low BMD with or without prevalent vertebral fractures. J Bone Miner Res 15:1384-1392 (Pubitemid 30413872)
38. Borgström F., Zethraeus N., Johnell O., Lidgren L., Ponzer S., Svensson O., Abdon P., Ornstein E., Lunsjö K., Thorngren K.G., Sernbo I., Rehnberg C., Jönsson B. 2006 Costs and quality of life associated with osteoporosis-related fractures in Sweden. Osteoporos Int 17:637-650
39. Kanis J.A., Johnell O., Oden A., Borgstrom F., Zethraeus N., De Laet C., Jonsson B. 2004 The risk and burden of vertebral fractures in Sweden. Osteoporos Int 15:20-26 (Pubitemid 38252435)
40. Tosteson A.N., Gabriel S.E., Grove M.R., Moncur M.M., Kneeland T.S., Melton 3rd L.J. 2001 3rd, Impact of hip and vertebral fractures on quality-adjusted life years. Osteoporos Int 12:1042-1049 (Pubitemid 34105976)